These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33483816)

  • 1. Factors Associated with Osteoporosis Management Among Veterans Who Received Androgen Deprivation Therapy for Prostate Cancer.
    Solimeo SL; Lund BC; McCoy KD; Sarrazin MV; Hoffman R
    J Gen Intern Med; 2021 Oct; 36(10):3270-3272. PubMed ID: 33483816
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy.
    D'Alesio V; Salvig BE; Fourakre TN
    Consult Pharm; 2011 Jan; 26(1):43-7. PubMed ID: 21224198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Diethylstilbesterol revised: androgen deprivation, osteoporosis and prostate cancer.
    Pitts WR
    J Urol; 2002 Nov; 168(5):2131-2. PubMed ID: 12394735
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer treated with androgen deprivation therapy has consequences for bone.
    Adler RA
    Endocrine; 2014 Apr; 45(3):339-40. PubMed ID: 24366636
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?
    Turco F; Tucci M; Buttigliero C
    Minerva Urol Nephrol; 2021 Dec; 73(6):870-872. PubMed ID: 35144376
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE.
    Gong J; Posadas EM
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: Bone density testing--essential or extraneous?
    Yu EY
    Nat Rev Urol; 2013 Jan; 10(1):11-2. PubMed ID: 23229500
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications of androgen-deprivation therapy for prostate cancer.
    Holzbeierlein JM; Castle EP; Thrasher JB
    Clin Prostate Cancer; 2003 Dec; 2(3):147-52. PubMed ID: 15040857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
    Owen PJ; Daly RM; Livingston PM; Fraser SF
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety.
    Labban M; Alkassis M; Alkhatib K; Briggs L; Cole AP; Kibel AS; Trinh QD
    Urol Clin North Am; 2022 May; 49(2):309-321. PubMed ID: 35428436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial).
    Mulder MB; Birnie E; van Dijck-van Boetzelaer C; van de Geijn GJ; Boevé E; Westerman EM; Hamberg P
    Acta Oncol; 2021 Apr; 60(4):539-543. PubMed ID: 33356721
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.